Therapeutic vaccination against chronic hepatitis C virus infection

Antiviral Research

Volumn 96, Issue 1, 2012, Pages 36-50

  Ip, Peng Peng ^a   Nijman, Hans W ^a   Wilschut, Jan ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Therapeutic vaccines

Indexed keywords

ADENOVIRUS VECTOR; BOCEPREVIR; CHRONVAC C; DNA VACCINE; ERYTHROPOIETIN; GI 5005; HEPATITIS C VACCINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ALPHA VIRUS; ANEMIA; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DEPRESSION; DRUG ERUPTION; FLU LIKE SYNDROME; HEPATITIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SACCHAROMYCES CEREVISIAE; TREATMENT RESPONSE; VACCINATION; VIRAL CLEARANCE; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; VACCINATION; VIRAL VACCINES;

HEPATITIS C VIRUS;

EID: 84866926462     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.07.006     Document Type: Review

References (182)

1. Anon Hepatitis C: global prevalence. Wkly Epidemiol. Rec. 1997, 72:341-344.
2. Ahlen G., Nystrom J., Pult I., Frelin L., Hultgren C., Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J. Infect. Dis. 2005, 192:2112-2116.
3. + T cells. J. Immunol. 2007, 179:4741-4753.
4. Alvarez-Lajonchere L., Shoukry N.H., Gra B., Amador-Canizares Y., Helle F., Bedard N., Guerra I., Drouin C., Dubuisson J., Gonzalez-Horta E.E., Martinez G., Marante J., Cinza Z., Castellanos M., Duenas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J. Viral Hepatol. 2009, 16:156-167.
5. Arribillaga L., Sarobe P., Arina A., Gorraiz M., Borras-Cuesta F., Ruiz J., Prieto J., Chen L., Melero I., Lasarte J.J. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005, 23:3493-3499.
6. + T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 2005, 175:4686-4696.
7. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., Poordad F., Goodman Z.D., Sings H.L., Boparai N., Burroughs M., Brass C.A., Albrecht J.K., Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1207-1217.
8. Banchereau J., Schuler-Thurner B., Palucka A.K., Schuler G. Dendritic cells as vectors for therapy. Cell 2001, 106:271-274.
9. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., Meyer J., Huddart R., Smith K., Townsend R., Brown A., Antrobus R., Ammendola V., Naddeo M., O'Hara G., Willberg C., Harrison A., Grazioli F., Esposito M.L., Siani L., Traboni C., Oo Y., Adams D., Hill A., Colloca S., Nicosia A., Cortese R., Klenerman P. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 2012, 4:115ra111.
10. Barnes E., Salio M., Cerundolo V., Francesco L., Pardoll D., Klenerman P., Cox A. Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J. Viral Hepatol. 2008, 15:219-228.
11. Bartosch B., Thimme R., Blum H.E., Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J. Hepatol. 2009, 51:810-820.
12. Battegay M., Fikes J., Di Bisceglie A.M., Wentworth P.A., Sette A., Celis E., Ching W.M., Grakoui A., Rice C.M., Kurokohchi K., et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 1995, 69:2462-2470.
13. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
14. Branch A.D., Stump D.D., Gutierrez J.A., Eng F., Walewski J.L. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin. Liver Dis. 2005, 25:105-117.
15. Brinster C., Chen M., Boucreux D., Paranhos-Baccala G., Liljestrom P., Lemmonier F., Inchauspe G. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 2002, 83:369-381.
16. Burlone M.E., Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 2009, 90:1055-1070.
17. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351:1320-1325.
18. Capone S., Meola A., Ercole B.B., Vitelli A., Pezzanera M., Ruggeri L., Davies M.E., Tafi R., Santini C., Luzzago A., Fu T.M., Bett A., Colloca S., Cortese R., Nicosia A., Folgori A. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 2006, 80:1688-1699.
19. Capone S., Zampaglione I., Vitelli A., Pezzanera M., Kierstead L., Burns J., Ruggeri L., Arcuri M., Cappelletti M., Meola A., Ercole B.B., Tafi R., Santini C., Luzzago A., Fu T.M., Colloca S., Ciliberto G., Cortese R., Nicosia A., Fattori E., Folgori A. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol. 2006, 177:7462-7471.
20. Casares N., Rudilla F., Arribillaga L., Llopiz D., Riezu-Boj J.I., Lozano T., Lopez-Sagaseta J., Guembe L., Sarobe P., Prieto J., Borras-Cuesta F., Lasarte J.J. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J. Immunol. 2010, 185:5150-5159.
21. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K.A., Dubey S., Zhu D.M., Nawrocki D., Mach H., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith J.G., Wang S., Liu X., Guan L., Long R., Trigona W., Heidecker G.J., Perry H.C., Persaud N., Toner T.J., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B., Emini E.A., Shiver J.W. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 2003, 77:6305-6313.
22. Castellanos M., Cinza Z., Dorta Z., Veliz G., Vega H., Lorenzo I., Ojeda S., Duenas-Carrera S., Alvarez-Lajonchere L., Martinez G., Ferrer E., Limonta M., Linares M., Ruiz O., Acevedo B., Torres D., Marquez G., Herrera L., Arus E. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J. Gene Med. 2010, 12:107-116.
23. Cerny A., McHutchison J.G., Pasquinelli C., Brown M.E., Brothers M.A., Grabscheid B., Fowler P., Houghton M., Chisari F.V. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 1995, 95:521-530.
24. Cerundolo V., Hermans I.F., Salio M. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 2004, 5:7-10.
25. Chang K.M. Regulatory T cells in hepatitis C virus infection. Hepatol. Res. 2007, 37(Suppl. 3):S327-330.
26. Chen A., Ahlen G., Brenndorfer E.D., Brass A., Holmstrom F., Chen M., Soderholm J., Milich D.R., Frelin L., Sallberg M. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination. J. Immunol. 2011, 186:5107-5118.
27. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 1994, 91:1294-1298.
28. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
29. Chua B.Y., Eriksson E.M., Brown L.E., Zeng W., Gowans E.J., Torresi J., Jackson D.C. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008, 26:4866-4875.
30. Coban C., Philipp M.T., Purcell J.E., Keister D.B., Okulate M., Martin D.S., Kumar N. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect. Immun. 2004, 72:253-259.
31. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., Siani L., Naddeo M., Grazioli F., Esposito M.L., Ambrosio M., Sparacino A., Bartiromo M., Meola A., Smith K., Kurioka A., O'Hara G.A., Ewer K.J., Anagnostou N., Bliss C., Hill A.V., Traboni C., Klenerman P., Cortese R., Nicosia A. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 2012, 4:115ra112.
32. Cox A.L., Mosbruger T., Mao Q., Liu Z., Wang X.H., Yang H.C., Sidney J., Sette A., Pardoll D., Thomas D.L., Ray S.C. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 2005, 201:1741-1752.
33. Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr. Opin. Immunol. 2009, 21:179-186.
34. Crispe I.N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 2003, 3:51-62.
35. + T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J. Clin. Invest. 2009, 119:376-386.
36. Desjardins D., Huret C., Dalba C., Kreppel F., Kochanek S., Cosset F.L., Tangy F., Klatzmann D., Bellier B. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J. Gene Med. 2009, 11:313-325.
37. Diaz-Valdes N., Manterola L., Belsue V., Riezu-Boj J.I., Larrea E., Echeverria I., Llopiz D., Lopez-Sagaseta J., Lerat H., Pawlotsky J.M., Prieto J., Lasarte J.J., Borras-Cuesta F., Sarobe P. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2011, 53:23-31.
38. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 1997, 71:6011-6019.
39. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346:1006-1007.
40. Donnelly J.J., Ulmer J.B., Liu M.A. DNA vaccines. Life Sci. 1997, 60:163-172.
41. Dore G.J., Matthews G.V., Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr. Opin. HIV AIDS 2011, 6:508-513.
42. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., Jones C.T., Schoggins J.W., Catanese M.T., Burton D.R., Law M., Rice C.M., Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
43. Dreux M., Cosset F.L. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J. Viral Hepatol. 2007, 14(Suppl 1):68-76.
44. Echeverria I., Pereboev A., Silva L., Zabaleta A., Riezu-Boj J.I., Bes M., Cubero M., Borras-Cuesta F., Lasarte J.J., Esteban J.I., Prieto J., Sarobe P. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology 2011, 54:28-37.
45. Echeverria I., Zabaleta A., Silva L., Diaz-Valdes N., Riezu-Boj J.I., Lasarte J.J., Borras-Cuesta F., Civeira M.P., Prieto J., Sarobe P. Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C). J. Viral Hepatol. 2008, 15:782-789.
46. El-Gogo S., Staib C., Lasarte J.J., Sutter G., Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J. Gene Med. 2008, 10:177-186.
47. Encke J., Bernardin J., Geib J., Barbakadze G., Bujdoso R., Stremmel W. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. World J. Gastroenterol. 2006, 12:7118-7125.
48. Encke J., Geissler M., Stremmel W., Wands J.R. DNA-based immunization breaks tolerance in a hepatitis C virus transgenic mouse model. Hum. Vaccine 2006, 2:78-83.
49. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
50. Fafi-Kremer S., Fofana I., Soulier E., Carolla P., Meuleman P., Leroux-Roels G., Patel A.H., Cosset F.L., Pessaux P., Doffoel M., Wolf P., Stoll-Keller F., Baumert T.F. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med. 2010, 207:2019-2031.
51. Fattori E., Zampaglione I., Arcuri M., Meola A., Ercole B.B., Cirillo A., Folgori A., Bett A., Cappelletti M., Sporeno E., Cortese R., Nicosia A., Colloca S. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther. 2006, 13:1088-1096.
52. Firbas C., Boehm T., Buerger V., Schuller E., Sabarth N., Jilma B., Klade C.S. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine 2010, 28:2397-2407.
53. Forns X., Thimme R., Govindarajan S., Emerson S.U., Purcell R.H., Chisari F.V., Bukh J. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl. Acad. Sci. USA 2000, 97:13318-13323.
54. Fournillier A., Gerossier E., Evlashev A., Schmitt D., Simon B., Chatel L., Martin P., Silvestre N., Balloul J.M., Barry R., Inchauspe G. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007, 25:7339-7353.
55. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
56. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., El Khoby T., Abdel-Wahab Y., Aly Ohn E.S., Anwar W., Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-891.
57. Frelin L., Ahlen G., Alheim M., Weiland O., Barnfield C., Liljestrom P., Sallberg M. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther. 2004, 11:522-533.
58. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
59. Garrone P., Fluckiger A.C., Mangeot P.E., Gauthier E., Dupeyrot-Lacas P., Mancip J., Cangialosi A., Du Chene I., LeGrand R., Mangeot I., Lavillette D., Bellier B., Cosset F.L., Tangy F., Klatzmann D., Dalba C. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 2011, 3:94ra71.
60. Gastaminza P., Cheng G., Wieland S., Zhong J., Liao W., Chisari F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82:2120-2129.
61. Gehring S., Gregory S.H., Kuzushita N., Wands J.R. Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J. Med. Virol. 2005, 75:249-257.
62. Gehring S., Gregory S.H., Wintermeyer P., Aloman C., Wands J.R. Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin. Vaccine Immunol. 2009, 16:163-171.
63. Gelderblom H.C., Nijhuis L.E., de Jong E.C., te Velde A.A., Pajkrt D., Reesink H.W., Beld M.G., van Deventer S.J., Jansen P.L. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int. 2007, 27:944-953.
64. Gill H.S., Soderholm J., Prausnitz M.R., Sallberg M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther. 2010, 17:811-814.
65. + T cells. J. Virol. 2009, 83:9122-9130.
66. Goutagny N., Vieux C., Decullier E., Ligeoix B., Epstein A., Trepo C., Couzigou P., Inchauspe G., Bain C. Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J. Infect. Dis. 2004, 189:1646-1655.
67. Gowans E.J., Roberts S., Jones K., Dinatale I., Latour P.A., Chua B., Eriksson E.M., Chin R., Li S., Wall D.M., Sparrow R.L., Moloney J., Loudovaris M., Ffrench R., Prince H.M., Hart D., Zeng W., Torresi J., Brown L.E., Jackson D.C. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J. Hepatol. 2010, 53:599-607.
68. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
69. Habersetzer F., Honnet G., Bain C., Maynard-Muet M., Leroy V., Zarski J.P., Feray C., Baumert T.F., Bronowicki J.P., Doffoel M., Trepo C., Agathon D., Toh M.L., Baudin M., Bonnefoy J.Y., Limacher J.M., Inchauspe G. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011, 141(890-899):e891-894.
70. Haller A.A., Lauer G.M., King T.H., Kemmler C., Fiolkoski V., Lu Y., Bellgrau D., Rodell T.C., Apelian D., Franzusoff A., Duke R.C. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007, 25:1452-1463.
71. He X.S., Rehermann B., Lopez-Labrador F.X., Boisvert J., Cheung R., Mumm J., Wedemeyer H., Berenguer M., Wright T.L., Davis M.M., Greenberg H.B. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA 1999, 96:5692-5697.
72. Hiranuma K., Tamaki S., Nishimura Y., Kusuki S., Isogawa M., Kim G., Kaito M., Kuribayashi K., Adachi Y., Yasutomi Y. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 1999, 80(Pt 1):187-193.
73. Inovio, 2010. Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology, pp. Inovio Pharmaceuticals, Inc Web Site.
74. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
75. Jirmo A.C., Koya R.C., Sundarasetty B.S., Pincha M., Yu G.Y., Lai M., Bakshi R., Schlaphoff V., Grabowski J., Behrens G., Wedemeyer H., Stripecke R. Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses. Vaccine 2010, 28:922-933.
76. Keck Z.Y., Sung V.M., Perkins S., Rowe J., Paul S., Liang T.J., Lai M.M., Foung S.K. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 2004, 78:7257-7263.
77. Khattak M.F., Salamat N., Bhatti F.A., Qureshi T.Z. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J. Pak. Med. Assoc. 2002, 52:398-402.
78. Kim A.Y., Kuntzen T., Timm J., Nolan B.E., Baca M.A., Reyor L.L., Berical A.C., Feller A.J., Johnson K.L., Schulze zur Wiesch J., Robbins G.K., Chung R.T., Walker B.D., Carrington M., Allen T.M., Lauer G.M. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011, 140:686-696. e681.
79. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S., Blum H., Buschle M., Jelovcan S., Buerger V., Tauber E., Frisch J., Manns M.P. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134:1385-1395.
80. Klinman D.M., Conover J., Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 1999, 67:5658-5663.
81. Klinman D.M., Takeno M., Ichino M., Gu M., Yamshchikov G., Mor G., Conover J. DNA vaccines: safety and efficacy issues. Springer Semin. Immunopathol. 1997, 19:245-256.
82. Kurokohchi K., Akatsuka T., Pendleton C.D., Takamizawa A., Nishioka M., Battegay M., Feinstone S.M., Berzofsky J.A. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J. Virol. 1996, 70:232-240.
83. Kuyper L.M., Collins C.L., Kerr T., Hogg R.S., Li K., Tyndall M.W., Montaner J.S., Wood E. The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia. Can. J. Infect. Dis. Med. Microbiol. 2005, 16:225-229.
84. Kuzushita N., Gregory S.H., Monti N.A., Carlson R., Gehring S., Wands J.R. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology 2006, 130:453-464.
85. Lambeck A.J., Nijman H.W., Hoogeboom B.N., Regts J., de Mare A., Wilschut J., Daemen T. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine 2010, 28:4275-4282.
86. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., Robbins G.K., Casson D.R., Reiser M., Dusheiko G., Allen T.M., Chung R.T., Walker B.D., Klenerman P. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004, 127:924-936.
87. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., Sakellariou G., Intrator L., Bartosch B., Pawlotsky J.M., Cosset F.L. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 2005, 79:6023-6034.
88. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., Ball J.K., McKeating J.A., Kneteman N.M., Burton D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14:25-27.
89. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 2000, 191:1499-1512.
90. Lemon S.M., McKeating J.A., Pietschmann T., Frick D.N., Glenn J.S., Tellinghuisen T.L., Symons J., Furman P.A. Development of novel therapies for hepatitis C. Antiviral Res. 2010, 86:79-92.
91. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C., Gale M., Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 2005, 102:2992-2997.
92. Li Y.P., Kang H.N., Babiuk L.A., Liu Q. Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World J. Gastroenterol. 2006, 12:7126-7135.
93. + T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J. Virol. 2008, 82:7492-7503.
94. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
95. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M., McKeating J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2004, 101:10149-10154.
96. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 1999, 189:587-592.
97. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
98. Mansilla C., Gorraiz M., Martinez M., Casares N., Arribillaga L., Rudilla F., Echeverria I., Riezu-Boj J.I., Sarobe P., Borras-Cuesta F., Prieto J., Lasarte J.J. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J. Hepatol. 2009, 51:520-527.
99. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 1995, 69:5087-5094.
100. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 1996, 184:1953-1962.
101. Matsui M., Moriya O., Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003, 21:1629-1639.
102. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010, 120:4546-4557.
103. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., Strathdee S.A., Vlahov D., Thomas D.L. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
104. Meuleman P., Bukh J., Verhoye L., Farhoudi A., Vanwolleghem T., Wang R.Y., Desombere I., Alter H., Purcell R.H., Leroux-Roels G. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011, 53:755-762.
105. Meunier J.C., Russell R.S., Goossens V., Priem S., Walter H., Depla E., Union A., Faulk K.N., Bukh J., Emerson S.U., Purcell R.H. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 2008, 82:966-973.
106. + T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J. Immunol. 2011, 186:2355-2364.
107. Mine T., Sato Y., Noguchi M., Sasatomi T., Gouhara R., Tsuda N., Tanaka S., Shomura H., Katagiri K., Rikimaru T., Shichijo S., Kamura T., Hashimoto T., Shirouzu K., Yamada A., Todo S., Itoh K., Yamana H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin. Cancer Res. 2004, 10:929-937.
108. Mizukoshi E., Eisenbach C., Edlin B.R., Newton K.P., Raghuraman S., Weiler-Normann C., Tobler L.H., Busch M.P., Carrington M., McKeating J.A., O'Brien T.R., Rehermann B. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J. Infect. Dis. 2008, 198:203-212.
109. Nakamoto N., Cho H., Shaked A., Olthoff K., Valiga M.E., Kaminski M., Gostick E., Price D.A., Freeman G.J., Wherry E.J., Chang K.M. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009, 5:e1000313.
110. Naslund T.I., Kostic L., Nordstrom E.K., Chen M., Liljestrom P. Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol. J. 2011, 8:36.
111. Nattermann J., Schneiders A.M., Leifeld L., Langhans B., Schulz M., Inchauspe G., Matz B., Brackmann H.H., Houghton M., Sauerbruch T., Spengler U. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). J. Hepatol. 2005, 42:499-504.
112. + T-cell failure in chronic hepatitis C virus infection. Hepatology 2008, 47:1824-1836.
113. + HRPC patients. Prostate 2005, 63:1-12.
114. Ogata N., Alter H.J., Miller R.H., Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. USA 1991, 88:3392-3396.
115. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., Thomas D.L., Cox A.L. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324.
116. Park S.H., Lee S.R., Hyun B.H., Kim B.M., Sung Y.C. Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine 2008, 26:3978-3983.
117. Pearlman B.L. Hepatitis C treatment update. Am. J. Med. 2004, 117:344-352.
118. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., Patel A.H., Meisel H., Baumert J., Viazov S., Rispeter K., Blum H.E., Roggendorf M., Baumert T.F. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 2007, 104:6025-6030.
119. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
120. Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., Rice C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886.
121. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.P. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
122. Prentoe J., Jensen T.B., Meuleman P., Serre S.B., Scheel T.K., Leroux-Roels G., Gottwein J.M., Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 2011, 85:2224-2234.
123. Qiu Q., Wang R.Y., Jiao X., Jin B., Sugauchi F., Grandinetti T., Alter H.J., Shih J.W. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 2008, 26:5527-5534.
124. + T cells and antiviral immunity. Immunity 2004, 20:47-58.
125. Ramirez J.C., Gherardi M.M., Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 2000, 74:923-933.
126. Ray R., Meyer K., Banerjee A., Basu A., Coates S., Abrignani S., Houghton M., Frey S.E., Belshe R.B. Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J. Infect. Dis. 2010, 202:862-866.
127. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 2009, 119:1745-1754.
128. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5:215-229.
129. Riezebos-Brilman A., Regts J., Freyschmidt E.J., Dontje B., Wilschut J., Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther. 2005, 12:1410-1414.
130. Riezebos-Brilman A., Walczak M., Regts J., Rots M.G., Kamps G., Dontje B., Haisma H.Y., Wilschut J., Daemen T. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther. 2007, 14:1695-1704.
131. Rollier C., Verschoor E.J., Paranhos-Baccala G., Drexhage J.A., Verstrepen B.E., Berland J.L., Himoudi N., Barnfield C., Liljestrom P., Lasarte J.J., Ruiz J., Inchauspe G., Heeney J.L. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J. Infect. Dis. 2005, 192:920-929.
132. Sainz B., Barretto N., Martin D.N., Hiraga N., Imamura M., Hussain S., Marsh K.A., Yu X., Chayama K., Alrefai W.A., Uprichard S.L. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18:281-285.
133. Saito T., Owen D.M., Jiang F., Marcotrigiano J., Gale M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008, 454:523-527.
134. Salloum S., Oniangue-Ndza C., Neumann-Haefelin C., Hudson L., Giugliano S., aus dem Siepen M., Nattermann J., Spengler U., Lauer G.M., Wiese M., Klenerman P., Bright H., Scherbaum N., Thimme R., Roggendorf M., Viazov S., Timm J. Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J. Virol. 2008, 82:11803-11812.
135. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
136. + T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007, 25:6793-6806.
137. Schulick A.H., Vassalli G., Dunn P.F., Dong G., Rade J.J., Zamarron C., Dichek D.A. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Invest. 1997, 99:209-219.
138. Segal B.M., Klinman D.M., Shevach E.M. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 1997, 158:5087-5090.
139. Semmo N., Lucas M., Krashias G., Lauer G., Chapel H., Klenerman P. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood 2006, 107:4570-4571.
140. Shi L., Liu S., Fan G.X., Sheng L., Ren H.X., Yuan Y.K. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes. Viral Immunol. 2006, 19:702-711.
141. Shirai M., Arichi T., Nishioka M., Nomura T., Ikeda K., Kawanishi K., Engelhard V.H., Feinstone S.M., Berzofsky J.A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 1995, 154:2733-2742.
142. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., Franzusoff A., Duke R.C., Wilson C.C. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat. Med. 2001, 7:625-629.
143. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 2004, 78:2666-2673.
144. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., Lifton M.A., Essex M., Walker B.D., Goudsmit J., Havenga M.J., Barouch D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 2005, 174:7179-7185.
145. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol. Ther. 2004, 10:616-629.
146. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 2002, 99:15661-15668.
147. Thimme R., Neumann-Haefelin C., Boettler T., Blum H.E. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol. Chem. 2008, 389:457-467.
148. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001, 194:1395-1406.
149. Timm J., Lauer G.M., Kavanagh D.G., Sheridan I., Kim A.Y., Lucas M., Pillay T., Ouchi K., Reyor L.L., Schulze zur Wiesch J., Gandhi R.T., Chung R.T., Bhardwaj N., Klenerman P., Walker B.D., Allen T.M. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 2004, 200:1593-1604.
150. Torresi J., Bharadwaj M., Jackson D.C., Gowans E.J. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr. Drug Targets 2004, 5:41-56.
151. Uebelhoer L., Han J.H., Callendret B., Mateu G., Shoukry N.H., Hanson H.L., Rice C.M., Walker C.M., Grakoui A. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 2008, 4:e1000143.
152. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
153. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., Mori C., Missale G., Ferrari C. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006, 44:126-139.
154. + lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 2002, 76:12423-12434.
155. + T cells: diversity specialists. Immunol. Rev. 2006, 211:225-235.
156. Vanwolleghem T., Bukh J., Meuleman P., Desombere I., Meunier J.C., Alter H., Purcell R.H., Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 2008, 47:1846-1855.
157. Verstrepen B.E., Depla E., Rollier C.S., Mares G., Drexhage J.A., Priem S., Verschoor E.J., Koopman G., Granier C., Dreux M., Cosset F.L., Maertens G., Heeney J.L. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J. Infect. Dis. 2011, 204:837-844.
158. Vidalin O., Fournillier A., Renard N., Chen M., Depla E., Boucreux D., Brinster C., Baumert T., Nakano I., Fukuda Y., Liljestrom P., Trepo C., Inchauspe G. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Virology 2000, 276:259-270.
159. Walczak M., de Mare A., Riezebos-Brilman A., Regts J., Hoogeboom B.N., Visser J.T., Fiedler M., Jansen-Durr P., van der Zee A.G., Nijman H.W., Wilschut J., Daemen T. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol. Pharm. 2011, 8:65-77.
160. Ward S., Lauer G., Isba R., Walker B., Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin. Exp. Immunol. 2002, 128:195-203.
161. + T cells in chronic hepatitis C virus infection. J. Immunol. 2002, 169:3447-3458.
162. Weiner A., Erickson A.L., Kansopon J., Crawford K., Muchmore E., Hughes A.L., Houghton M., Walker C.M. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. USA 1995, 92:2755-2759.
163. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
164. Wintermeyer P., Gehring S., Eken A., Wands J.R. Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells. J. Viral Hepatol. 2010, 17:705-713.
165. Wintermeyer P., Wands J.R. Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J. Gastroenterol. 2007, 42:424-432.
166. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
167. Wuest T., Both G.W., Prince A.M., Hofmann C., Loser P. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004, 22:2717-2721.
168. Xia G.-L., Liu C.-B., Cao H.-L., Bi S.-L., Zhan M.-Y., Su C.-A., Nan J.-H., Qi X.-Q. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int. Hepatol. Commun. 1996, 5:62-73.
169. Xiang M., Eisenbach C., Lupu C.M., Ernst E., Stremmel W., Encke J. Induction of antigen-specific immune responses in vivo after vaccination with dendritic cells transduced with adenoviral vectors encoding hepatitis C virus NS3. Viral Immunol. 2006, 19:210-219.
170. Yajima N., Yamanaka R., Mine T., Tsuchiya N., Homma J., Sano M., Kuramoto T., Obata Y., Komatsu N., Arima Y., Yamada A., Shigemori M., Itoh K., Tanaka R. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 2005, 11:5900-5911.
171. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 2007, 3:e108.
172. Yu H., Babiuk L.A., van Drunen Littel-van den Hurk S. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J. Gen. Virol. 2004, 85:1533-1543.
173. Yu H., Babiuk L.A., van Drunen Littel-van den Hurk S. Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA. Vaccine 2007, 25:1701-1711.
174. Yu H., Babiuk L.A., van Drunen Littel-van den Hurk S. Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J. Viral Hepatol. 2008, 15:459-470.
175. Yutani S., Komatsu N., Shichijo S., Yoshida K., Takedatsu H., Itou M., Kuromatu R., Ide T., Tanaka M., Sata M., Yamada A., Itoh K. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 2009, 100:1935-1942.
176. Yutani S., Yamada A., Yoshida K., Takao Y., Tamura M., Komatsu N., Ide T., Tanaka M., Sata M., Itoh K. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007, 25:7429-7435.
177. Zabaleta A., Arribillaga L., Llopiz D., Dotor J., Lasarte J.J., Prieto J., Borras-Cuesta F., Esteban J.I., Quer J., Vayreda F., Sarobe P. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Res. 2007, 74:25-35.
178. Zabaleta A., Llopiz D., Arribillaga L., Silva L., Riezu-Boj J.I., Lasarte J.J., Borras-Cuesta F., Prieto J., Sarobe P. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol. Ther. 2008, 16:210-217.
179. Zeisel M.B., Fafi-Kremer S., Fofana I., Barth H., Stoll-Keller F., Doffoel M., Baumert T.F. Neutralizing antibodies in hepatitis C virus infection. World J. Gastroenterol. 2007, 13:4824-4830.
180. Zhu L.X., Liu J., Ye Y., Xie Y.H., Kong Y.Y., Li G.D., Wang Y. A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J. Gastroenterol. 2004, 10:2488-2492.
181. Zhu W., Chang Y., Wu C., Han Q., Pei R., Lu M., Chen X. The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice. Clin. Vaccine Immunol. 2010, 17:1139-1147.
182. Zubkova I., Choi Y.H., Chang E., Pirollo K., Uren T., Watanabe H., Wells F., Kachko A., Krawczynski K., Major M.E. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009, 27:2594-2602.